Tim Ravenscroft, Boro Dropulic, Mauro Ferrari, Thomas Beier, Richard Pfenniger, David Eichler

Jan 31, 2008

Premium

Lentigen has appointed Tim Ravenscroft as its CEO, replacing company founder Boro Dropulic, who continues to serve as president and CSO.

Before joining Lenitgen, Ravenscroft was president of Bristol-Myers Squibb Medical Imaging. He has also held various management positions at Dupont Pharmaceutical and Glaxo Wellcome.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Last of the Northern White Rhinoceroses, Sequenced

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

DNA Phenotyping Allowed in Bavaria

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Thanks for the Stress, Dad

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

This Week in Science

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Featured White Papers

The Ultimate Guide to Mouse Clinical Trials

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

How to Perform Successful CRISPR Experiments

High Throughput RT-qPCR for Gene Expression Analysis

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Main menu